John E Osborn. Show Affiliations »
Abstract
Mesh： See more » Adenine/analogs & derivativesAdenine/therapeutic useAngiogenesis Inhibitors/therapeutic useAnti-HIV Agents/therapeutic useAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBenzhydryl Compounds/therapeutic useBevacizumabBotulinum Toxins, Type A/therapeutic useCentral Nervous System Stimulants/therapeutic useDrug Industry/ethicsDrug Industry/legislation & jurisprudenceEthics, MedicalHumansLegislation, Drug/ethicsLegislation, Drug/trendsModafinilNeuromuscular Agents/therapeutic useOff-Label Use/ethicsOff-Label Use/legislation & jurisprudenceOrganophosphonates/therapeutic usePolicy MakingPublic Policy/legislation & jurisprudencePublic Policy/trendsRanibizumabTenofovirTreatment OutcomeTruth DisclosureUnited KingdomUnited StatesUnited States Food and Drug Administration
Substances： See more » Angiogenesis InhibitorsAnti-HIV AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBenzhydryl CompoundsCentral Nervous System StimulantsNeuromuscular AgentsOrganophosphonatesBevacizumabTenofovirBotulinum Toxins, Type AAdenineModafinilRanibizumab
Year: 2010 PMID： 20681438
Source DB: PubMed Journal: Yale J Health Policy Law Ethics ISSN： 1535-3532